About 1,668 results

ALLMedicine™ Ependymoma Center

Research & Reviews  628 results

Emerging Epigenetic Therapies for Brain Tumors.
https://doi.org/10.1007/s12017-021-08691-x 10.1177/1533033820960748 10.1371/journal.pone.0080865 10.1038/nature02871 10.1186/s40478-020-00942-5 10.18632/oncotarget.1408 10.1016/j.neuint.2014.06.002 10.1038/s41392-019-0095-0 10.1371/journal.pone.0025114 10.1093/nar/gkv703 10.1002/pmic.201800479 10.3390/cancers8030031 10.1038/nrg3074 10.18632/oncotarget.15206 10.1093/jnen/nlaa059 10.1016/j.semcancer.2008.01.008 10.1186/s40364-019-0174-y 10.1038/s41416-020-0814-x 10.1182/blood-2013-10-533604 10.1016/j.mam.2013.01.005 10.1016/j.canlet.2012.04.008 10.1016/j.gendis.2016.04.007 10.3389/fphar.2017.00495 10.1186/s40478-015-0206-2 10.1038/nn.4190 10.1200/JCO.19.03327 10.1158/1078-0432.CCR-10-0395 10.18632/oncotarget.20741 10.1038/nm.4293 10.15430/JCP.2019.24.2.79 10.1007/s12035-012-8349-7 10.1016/j.semcancer.2009.02.005 10.1038/s41572-019-0063-6 10.3389/fendo.2018.00402 10.1093/neuonc/noz150 10.1186/s40478-014-0180-0 10.1186/s13046-019-1180-5 10.1093/carcin/bgt182 10.1126/science.1236062 10.3389/fonc.2018.00448 10.1128/MCB.00332-09 10.1038/nature13387 10.1007/s10555-009-9188-5 10.1093/neuonc/nos281 10.1371/journal.pone.0024248 10.1001/jama.2017.18718 10.1007/s00401-011-0922-z 10.1038/nature10866 10.18632/oncotarget.362 10.3389/fonc.2012.00205 10.1093/neuonc/nov292 10.22034/APJCP.2018.19.9.2613 10.1093/neuonc/now016 10.4103/2230-973X.167646 10.1093/neuros/nyx262
Neuromolecular Medicine; Kukreja L, Li CJ et. al.

Oct 23rd, 2021 - Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and c...

Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups.
AJNR. American Journal of Neuroradiology; Sabin ND, Hwang SN et. al.

Oct 23rd, 2021 - Posterior fossa type A (PFA) ependymomas have 2 molecular subgroups (PFA-1 and PFA-2) and 9 subtypes. Gene expression profiling suggests that PFA-1 and PFA-2 tumors have distinct developmental origins at different rostrocaudal levels of the brains...

Gliomas in children and adolescents: investigation of molecular alterations with a pote...
https://doi.org/10.1007/s00432-021-03813-1 10.1136/bcr-2016-217189 10.3390/ht7040039 10.1136/esmoopen-2015-000023 10.1093/neuonc/noaa222.324 10.1093/jnen/nlz140 10.1016/j.semcancer.2021.06.008 10.1007/s11060-017-2393-0 10.1158/2159-8290.CD-19-1030 10.1093/noajnl/vdab016 10.1158/1541-7786.MCR-17-0460 10.6004/jnccn.2017.0139 10.1007/s00432-018-02836-5 10.1016/j.wneu.2020.03.212 10.3389/fonc.2012.00105 10.3390/ijms21030753 10.1007/s11060-019-03377-8 10.1038/s41467-019-12187-5 10.1080/02688690903158809 10.1016/j.jmoldx.2018.06.009 10.1101/mcs.a001115 10.1016/j.jmoldx.2019.03.008 10.1186/s40478-017-0436-6 10.1016/j.apsb.2020.05.004 10.1158/0008-5472.CAN-08-2097 10.1007/s00018-011-0898-9 10.1097/PAS.0000000000000788 10.1101/gad.200907.112 10.1007/s00401-015-1405-4 10.3390/cancers10040105 10.1016/j.wneu.2020.07.015 10.1093/jncics/pky079 10.1093/neuonc/noab106 10.1093/neuonc/nos125 10.1136/bcr-2018-228248 10.1007/s00381-020-04852-8 10.3171/2018.10.PEDS18377 10.1016/S1470-2045(20)30026-7 10.1038/nature10833 10.1007/s00234-010-0699-0 10.1097/00005072-196404000-00004 10.3389/fonc.2020.574974 10.1016/j.ccr.2012.08.024 10.1038/nrc3655 10.11477/mf.1436204438 10.1111/bpa.12042 10.1093/neuonc/noab120 10.3389/fonc.2017.00033 10.1038/ng.2938 10.1016/j.ccr.2013.09.015 10.1016/j.cancergen.2020.12.005
Journal of Cancer Research and Clinical Oncology; Cabral de Carvalho Corrêa D, Tesser-Gamba F et. al.

Oct 10th, 2021 - Gliomas represent the most frequent central nervous system (CNS) tumors in children and adolescents. However, therapeutic strategies for these patients, based on tumor molecular profile, are still limited compared to the wide range of treatment op...

Treatment and outcome of intracranial ependymoma after first relapse in AIEOP 2 nd prot...
Neuro-oncology Massimino M, Barretta F et. al.

Oct 5th, 2021 - More than 40% of patients with intracranial ependymoma need a salvage treatment within 5 years after diagnosis, and no standard treatment is available as yet. We report the outcome after first relapse of 64 patients treated within the 2 nd AIEOP p...

Bicentric Treatment Outcomes following Proton Therapy for Non-Myxopapillary High-Grade ...
International Journal of Radiation Oncology, Biology, Phy... Indelicato DJ, Ioakeim-Ioannidou M et. al.

Oct 2nd, 2021 - Few studies report outcomes in children treated with radiation for non-myxopapillary ependymoma of the spinal cord, and little evidence exists to inform decisions regarding target volume and prescription dose. Moreover, virtually no mature outcome...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  10 results

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Sep 29th, 2021 - Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 1...

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Sep 5th, 2021 - Background: There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of pro...

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma

Apr 30th, 2021 - This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intratheca...

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma

Dec 21st, 2020 - This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain. The study's primary objective is to establish the maximum tolerated dose for infusions of 5-Azacytidine into the fou...

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Jul 17th, 2020 - The study will consist of 4 parallel groups of participants, one for each of the following primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and DIPG. A Simon's Optimal two-stage study design will be applied to each group a...

see more →

News  19 results

FDA Grants Rare Pediatric Disease Designation to WP1066 for Ependymoma

Apr 14th, 2021 - The FDA has granted a rare pediatric disease (RPD) designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.1 The FDA’s recognition of the h...

Optimizing Precision Medicine Approaches in Glioblastoma

Dec 20th, 2020 - Mark R. Gilbert, MD The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an endeavor eagerly embraced by researchers and patients alike, but the effort poses both opportunities and challe...

Dr. Upadhyaya on Radiation Therapy for Young Children with Ependymoma

Dec 20th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses radiation therapy for young children under the age of 3 who have ependymoma. He highlighted outcomes of the 10-year-long SJYC07 trial at the 2018 ASCO Annua...

Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain Tumors

Dec 4th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors. Drug development is challenging, explains Upadhyaya, especially as it relates to pediatric patie...

Dr. Upadhyaya on Risk Factors for Pediatric Ependymoma

Dec 4th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses risk factors for developing pediatric ependymoma. Most pediatric patients who are diagnosed with ependymoma are diagnosed without any known predisposition ...

see more →